More than 4.1 million Americans live with hepatitis C, a viral infection of the liver. That's one of several reasons why Jason Kolbert, a biotechnology analyst at Susquehanna Financial Group, advised "Squawk Box" viewers to stock up on therapy stocks.
The analyst pointed to Vertex Pharmaceuticals , for example, which leads the market with its VX-950 -- “probably the most potent drug in the field” for the disease, he said.
And expect consumers to use a combination of therapies, Kolbert said. Some 50% of people living with the disease are in need of ongoing help: “Half the people who have hepatitis C and take these therapies are cured,” he said. “But, the other half aren’t. And there are very few treatments available to them.”